PATENT CLAIM ANALYSIS

Application Number: 16335765
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["546", "070000"]

Abstract:
A method for treating small cell lung cancer (SCLC). In the method, a therapeutically effective amount of a compound of Formula I: wherein R 1 , R 2  and R 3  have the definitions disclosed in the specification is administered alone or in combination with one or more anticancer agents, or surgery, radiation therapy, chemotherapy, and/or targeted therapy.

Claim (Index 24):
The combination of  claim 17 , wherein the second anticancer agents is selected from the group consisting of irinotecan, etoposide, cisplatin, picoplatin, cyclophosphamide, doxorubicin, vincristine, topotecan, pemetrexed, carboplatin, gemcitabine, paclitaxel, vinorelbine, ifosphamide, erlotinib, gefitinib, afatinib, denosumab, Talazoparib, Veliparib, and LY294002.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 99.0
- Lexical Diversity: 1.33333
- Patent Class: 546.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13549572', '15745639', '13504943', '15309382', '11490438']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7956470642031392
- 35 USC 102 Novelty (BERT): 0.5456232191380357
- Combined Prediction Score: 0.770644679696629
- Mean Citation Score: 272.06953000000004
- Max Citation Score: 401.5671
- Similarity Product: 296.85998831999296

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test